Loading clinical trials...
Loading clinical trials...
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Conditions
Interventions
UGN-102
TURBT
Locations
139
United States
Arizona Institute of Urology, PLLC
Tucson, Arizona, United States
Loma Linda University Medical Center
Loma Linda, California, United States
Urology Group of Southern California
Los Angeles, California, United States
San Diego Clinical Trials
San Diego, California, United States
Providence Saint John's Health Center
Santa Monica, California, United States
Skyline Urology
Sherman Oaks, California, United States
Start Date
February 19, 2021
Primary Completion Date
March 17, 2023
Completion Date
March 17, 2023
Last Updated
June 6, 2024
NCT06257264
NCT07206225
NCT06857175
NCT04693377
NCT06253871
NCT04895709
Lead Sponsor
UroGen Pharma Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions